CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,778,147 | -68.8% | 127,300 | -61.5% | 0.09% | -72.9% |
| Q2 2023 | $18,543,042 | +1724.7% | 330,300 | +1221.2% | 0.33% | +1950.0% |
| Q4 2022 | $1,016,250 | -76.1% | 25,000 | -61.5% | 0.02% | -72.9% |
| Q3 2022 | $4,248,000 | -12.6% | 65,000 | -18.8% | 0.06% | -11.9% |
| Q2 2022 | $4,861,000 | +93.5% | 80,000 | +100.0% | 0.07% | +123.3% |
| Q1 2022 | $2,512,000 | -24.0% | 40,000 | -8.3% | 0.03% | -21.1% |
| Q4 2021 | $3,305,000 | -75.1% | 43,600 | -46.8% | 0.04% | -78.0% |
| Q2 2021 | $13,260,000 | +156.0% | 81,900 | +92.7% | 0.17% | +55.9% |
| Q1 2021 | $5,179,000 | -59.7% | 42,500 | -75.7% | 0.11% | -74.1% |
| Q2 2020 | $12,861,000 | +203.3% | 175,000 | +75.0% | 0.43% | +78.3% |
| Q1 2020 | $4,241,000 | -30.4% | 100,000 | 0.0% | 0.24% | +17.1% |
| Q4 2019 | $6,091,000 | +854.7% | 100,000 | +594.4% | 0.20% | +485.7% |
| Q3 2018 | $638,000 | -24.7% | 14,400 | 0.0% | 0.04% | -47.0% |
| Q2 2018 | $847,000 | – | 14,400 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |